AST Asterias Biotherapeutics Inc. Common Series A

-0.20  -7%
Previous Close 2.85
Open 2.90
Price To book 3.63
Market Cap 132443796
Shares 49,978,791
Volume 684,067
Short Ratio 27.02
Av. Daily Volume 140,976

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2017.
Non-small cell lung cancer (NSCLC)
Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20 million cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
Cervical spinal cord injury
Phase 2b planned for 2018.
Acute myeloid leukemia (AML)

Latest News

  1. ETFs with exposure to Asterias Biotherapeutics, Inc. : October 17, 2017
  2. Asterias Biotherapeutics Announces $10.4 Million Registered Direct Offering
  3. Asterias Announces Two Significant Developments for Spinal Cord Injury Program
  4. Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer
  5. Asterias’ AST-OPC1 Clinical Trial Will Continue as Planned Following Recommendation of Data Monitoring Committee
  6. ETFs with exposure to Asterias Biotherapeutics, Inc. : September 19, 2017
  7. Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
  8. Asterias Biotherapeutics to Present at Upcoming Conferences
  9. Preclinical Data Published in Peer-Reviewed Journal Stem Cells Translational Medicine Provides Scientific Framework for Asterias’ AST-OPC1 for the Treatment of Subacute Cervical Spinal Cord Injury
  10. Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 SCiStar Study
  11. Asterias Biotherapeutics posts 2Q loss
  12. Asterias Biotherapeutics Reports Second Quarter Financial Results and Reviews Recent Clinical Progress and Corporate Developments
  13. Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2
  14. Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial
  15. Former Quadriplegic Enrolled in Asterias’ SCiStar Study to Throw Ceremonial First Pitch at Major League Baseball Game
  16. Asterias Biotherapeutics to Present at Canaccord Genuity Growth Conference on August 10, 2017
  17. Asterias Biotherapeutics Opens Two Additional Clinical Sites for AST-OPC1 SCiStar Study
  18. Asterias Biotherapeutics to Report Second Quarter Results on August 14, 2017
  19. Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort